

Meningococcal Vaccines Work Group Update

Lorry Rubin, M.D.

Chair, Meningococcal Work Group
Advisory Committee on Immunization Practices

October 24, 2012

Working Group Members

- Marietta Vasquez- ACIP
- Doug Campos-Outcalt- ACIP
- Geoff Evans- HRSA
- Mike Brady- AAP
- Lucia Lee- FDA
- David Salisbury- UK
- William Schaffner- NFID
- Karen O'Brian- AAFP
- Jim Turner- ACHA
- Amy Middleman- SAM
- Martin Luta- CSTE
- Richard Clover
- Paul McKinney
- Paul Offit
- Georges Peter
- David Stephens
- Cody Meissner
- Michael Marcy
- Carol Baker
- Bill Atkinson
- Amanda Cohn- CDC
- Thomas Clark-CDC
- Nancy Messonnier- CDC
- Iyabode Beysolow – CDC
- Jonathan Duffy- CDC
- Shannon Stokley- CDC
- Ismael Ortega-Sanchez-CDC



Meningoocccal Vaccines for Infants and Toddlers

- MenACWY-D (Menactra, sanofi pasteur)
 - 2 dose series at 9 -23 months
- HibMenCY-TT (MenHibRix, GlaxoSmithKline)
 - 4 dose series at 2,4,6 and 12 months
 - Licensed in June 2012
- MenACWY-CRM (Menveo, Novartis)
 - Investigational vaccine for infants

Infant Meningococcal Recommendations

- ❑ **Recommendation for high-risk infants 9 through 23 months to receive 2 doses of MenACWY-D**

- ❑ **October 2011 ACIP meeting: presented Work Group rationale for no routine recommendation for infant meningococcal vaccines**
 - Declining disease rates now at historic lows
 - Low proportion of infant cases and deaths vaccine preventable: young age at onset; serogroup B cases
 - Multiple doses with potential need for booster doses

HibMenCY-TT

- ❑ Immunogenic against serogroups C and Y**
 - Does not protect against serogroups A, B, and W135
- ❑ Similar safety and immunogenicity to Hib compared to other Hib vaccines**
- ❑ Four doses (0.5 mL each) by intramuscular injection at 2, 4, 6, and 12 through 15 months of age.**
 - The first dose may be given as early as 6 weeks of age. The fourth dose may be given as late as 18 months of age.

Today's Session

- ❑ **Immunogenicity and safety of HibMenCY**
 - Response to 2 doses
 - Antibody persistence
- ❑ **GRADE evaluation of HibMenCY**
- ❑ **Considerations of Use of HibMenCY in infants**
- ❑ **Vote for vaccine recommendations for infants at increased risk for meningococcal disease**

Meningococcal Work Group: Additional Activities

- ❑ ACIP Meningococcal Vaccines Statement to be published in December 2012, MMWR R and R**
- ❑ Review of updated Hib Vaccines Policy Note**
 - Affirm recommendations by vote at February 2013 meeting**
- ❑ Anticipated licensure of MenACWY-CRM as a 4 dose infant series - developing guidance for use**
- ❑ Early thinking about the approach to serogroup B vaccines**